## Syngenta AG

## Interim Condensed Consolidated Financial Statements

*The following unaudited interim condensed consolidated financial statements and notes thereto have been prepared in accordance with IAS 34, “Interim Financial Reporting”, as disclosed in Note 1 below. They do not contain all of the information which IFRS Accounting Standards would require for a complete set of financial statements and should be read in conjunction with the annual consolidated financial statements.*

## Condensed Consolidated Income Statement

| for the six months ended June 30, ($m) | Notes | 2026 | 2025[1] |
|---|---|---|---|
| **Sales** | **5** | **8,025** | **7,936** |
| Cost of goods sold | | (4,616) | (4,716) |
| **Gross profit** | | **3,409** | **3,220** |
| Marketing and distribution | | (1,290) | (1,194) |
| Research and development | | (602) | (507) |
| General and administrative | | (401) | (346) |
| Other operating income | | 149 | 176 |
| Other operating expense | | (744) | (162) |
| **Operating income** | | **521** | **1,187** |
| Finance income | | 46 | 54 |
| Finance expense | | (279) | (334) |
| Currency gains/(losses), net | | 63 | 24 |
| Financial expense, net | | (170) | (256) |
| **Income before taxes** | | **351** | **931** |
| Income tax expense | | (173) | (350) |
| **Net income** | | **178** | **581** |
| Attributable to: | | | |
| Syngenta AG shareholder | | 177 | 579 |
| Non-controlling interests | | 1 | 2 |
| **Net income** | | **178** | **581** |

1 To be consistent with 2026, the 2025 comparative figures have been reclassified to present Other operating income and Other operating expense as separate categories, which were previously included within General and administrative expenses

All activities were in respect of continuing operations.

The accompanying notes form an integral part of the interim condensed consolidated financial statements.

## Condensed Consolidated Statement of Comprehensive Income

| **for the six months ended June 30,**<br>**($m)** | **2026** | **2025** |
|---|---|---|
| **Net income** | **178** | **581** |
| **Components of other comprehensive income/(loss) (OCI)** | | |
| Items that will not be reclassified to profit or loss: | | |
| Losses on equity investments at fair value through OCI | (22) | (16) |
| Remeasurement of defined benefit post-employment plans | 160 | 115 |
| Income tax relating to items that will not be reclassified to profit or loss | (23) | (8) |
| | 115 | 91 |
| Items that are or may be reclassified subsequently to profit or loss: | | |
| Gains/(losses) on derivatives designated as cash flow hedges and related hedging costs | 44 | 9 |
| Currency translation effects | (26) | 150 |
| Income tax relating to items that are or may be reclassified subsequently to profit or loss | (6) | 4 |
| | 12 | 163 |
| **Total OCI** | **127** | **254** |
| **Total comprehensive income** | **305** | **835** |
| Attributable to: | | |
| Syngenta AG shareholder | 304 | 833 |
| Non-controlling interests | 1 | 2 |
| **Total comprehensive income** | **305** | **835** |

All activities were in respect of continuing operations.

The accompanying notes form an integral part of the interim condensed consolidated financial statements.

During the six months ended June 30, 2026, in respect of cash flow hedges, gains of $38 million (2025: $15 million) were recognized in OCI and losses of $6 million (2025: gains of $6 million) were reclassified from OCI to profit or loss. Income tax of $6 million was debited (2025: $4 million credited) to OCI in respect of these movements.

## Condensed Consolidated Balance Sheet

| ($m) | Notes | June 30, 2026 | June 30, 2025 | December 31, 2025 |
|---|---|---|---|---|
| **Assets** | | | | |
| **Current assets:** | | | | |
| Cash and cash equivalents | 11 | 977 | 971 | 677 |
| Trade receivables | 11 | 7,338 | 7,076 | 5,605 |
| Other accounts receivable | 11 | 1,424 | 1,272 | 1,250 |
| Inventories | | 6,342 | 6,841 | 6,310 |
| Derivative and other financial assets | 11 | 558 | 991 | 453 |
| Other current assets | | 647 | 645 | 429 |
| Income taxes recoverable | | 276 | 226 | 198 |
| **Total current assets** | | **17,562** | **18,022** | **14,922** |
| **Non-current assets:** | | | | |
| Property, plant and equipment | | 4,104 | 4,207 | 4,229 |
| Right-of-use assets | | 824 | 782 | 812 |
| Intangible assets | | 7,746 | 7,467 | 7,631 |
| Deferred tax assets | | 1,504 | 1,716 | 1,476 |
| Financial and other non-current assets | 11 | 1,611 | 1,464 | 1,531 |
| Investments in associates and joint ventures | | 205 | 188 | 198 |
| **Total non-current assets** | | **15,994** | **15,824** | **15,877** |
| **Total assets** | | **33,556** | **33,846** | **30,799** |
| **Liabilities and equity** | | | | |
| **Current liabilities:** | | | | |
| Trade accounts payable | 11 | (6,720) | (6,507) | (5,926) |
| Contract liabilities | | (415) | (518) | (948) |
| Current financial debt and other financial liabilities | 10, 11 | (7,077) | (8,035) | (4,002) |
| Income taxes payable | | (922) | (748) | (797) |
| Other current liabilities | 11 | (1,598) | (1,041) | (1,514) |
| Provisions | | (667) | (177) | (895) |
| **Total current liabilities** | | **(17,399)** | **(17,026)** | **(14,082)** |
| **Non-current liabilities:** | | | | |
| Financial debt and other non-current liabilities | 10, 11 | (6,651) | (6,578) | (7,159) |
| Deferred tax liabilities | | (1,664) | (1,638) | (1,640) |
| Provisions | | (503) | (493) | (531) |
| **Total non-current liabilities** | | **(8,818)** | **(8,709)** | **(9,330)** |
| **Total liabilities** | | **(26,217)** | **(25,735)** | **(23,412)** |
| **Shareholder's equity:** | | | | |
| Total shareholder's equity | | (7,303) | (8,076) | (7,352) |
| Non-controlling interests | | (36) | (35) | (35) |
| **Total equity** | | **(7,339)** | **(8,111)** | **(7,387)** |
| **Total liabilities and equity** | | **(33,556)** | **(33,846)** | **(30,799)** |

The accompanying notes form an integral part of the interim condensed consolidated financial statements.

## Condensed Consolidated Cash Flow Statement

| for the six months ended June 30, ($m) | Notes | 2026 | 2025 |
|---|---|---|---|
| **Income before taxes** | | **351** | **931** |
| Reversal of non-cash and other reconciling items | 8 | 815 | 746 |
| **Cash (paid)/received in respect of:** | | | |
| Interest received | | 44 | 49 |
| Interest paid | | (293) | (330) |
| Other financial receipts | | 1 | 23 |
| Other financial payments | | (300) | (133) |
| Income taxes | | (136) | (183) |
| Restructuring costs | | (21) | (39) |
| Contributions to pension plans, excluding restructuring costs | | (39) | (60) |
| Other provisions | | (315) | (12) |
| **Operating cash flow before change in net working capital** | | **107** | **992** |
| **Change in net working capital:** | | | |
| Change in inventories | | (229) | (117) |
| Change in trade and other working capital assets | | (1,918) | (1,880) |
| Change in trade and other working capital liabilities | | 344 | (188) |
| **Cash flow used for operating activities** | | **(1,696)** | **(1,193)** |
| Additions to property, plant and equipment | | (152) | (165) |
| Purchases of intangible assets and capitalized development costs | | (332) | (340) |
| Purchases of investments in associates and other financial assets | | (1) | (43) |
| Proceeds from disposals of property, plant and equipment | | 30 | 8 |
| Proceeds from disposals of intangible and financial assets | | 97 | 9 |
| Business acquisitions, net of cash acquired | | - | (16) |
| Business divestments, net of cash divested | | 6 | 205 |
| **Cash flow used for investing activities** | | **(352)** | **(342)** |
| Proceeds from increase in interest-bearing debt | | 4,947 | 3,382 |
| Repayments of interest-bearing debt | | (2,610) | (1,959) |
| Proceeds from partial divestment of interest in subsidiary | | - | 21 |
| **Cash flow from financing activities** | | **2,337** | **1,444** |
| Net effect of currency translation on cash and cash equivalents | | 11 | 37 |
| **Net change in cash and cash equivalents** | | **300** | **(54)** |
| Cash and cash equivalents at the beginning of the period | | 677 | 1,025 |
| **Cash and cash equivalents at the end of the period** | | **977** | **971** |

The accompanying notes form an integral part of the interim condensed consolidated financial statements.

## Condensed Consolidated Statement of Changes in Equity

| ($m) | Issued share capital | Additional paid-in capital | Fair value reserves | Cumulative translation adjustment | Retained earnings | Total share-holder's equity | Non-controlling interests | Total equity |
|---|---|---|---|---|---|---|---|---|
| | Attributable to Syngenta AG shareholder | | | | | | | |
| **January 1, 2025** | **6** | **3,416** | **(55)** | **(3,464)** | **7,343** | **7,246** | **15** | **7,261** |
| Net income | - | - | - | - | 579 | 579 | 2 | 581 |
| OCI | - | - | (1) | 150 | 105 | 254 | - | 254 |
| **Total comprehensive income** | **-** | **-** | **(1)** | **150** | **684** | **833** | **2** | **835** |
| Transactions with owner: | | | | | | | | |
| Partial divestment of interest in subsidiary | - | - | - | - | 3 | 3 | 18 | 21 |
| Hedging gains and losses transferred to cost of inventory | - | - | (6) | - | - | (6) | - | (6) |
| **June 30, 2025** | **6** | **3,416** | **(62)** | **(3,314)** | **8,030** | **8,076** | **35** | **8,111** |
| | | | | | | | | |
| **January 1, 2026** | **6** | **3,416** | **(105)** | **(3,375)** | **7,410** | **7,352** | **35** | **7,387** |
| Net income | - | - | - | - | 177 | 177 | 1 | 178 |
| OCI | - | - | 17 | (26) | 136 | 127 | - | 127 |
| **Total comprehensive income** | **-** | **-** | **17** | **(26)** | **313** | **304** | **1** | **305** |
| Transactions with owner: | | | | | | | | |
| Distributions to shareholder | - | - | - | - | (350) | (350) | - | (350) |
| Hedging gains and losses transferred to cost of inventory | - | - | (3) | - | - | (3) | - | (3) |
| **June 30, 2026** | **6** | **3,416** | **(91)** | **(3,401)** | **7,373** | **7,303** | **36** | **7,339** |

The accompanying notes form an integral part of the interim condensed consolidated financial statements.

In June 2026 a dividend of $350 million was declared. This was paid to Syngenta's parent company, Syngenta Group (HK) Holdings Co. Ltd., in July 2026. No dividend was declared or paid in the six months ended June 30, 2025.

## Note 1: Basis of preparation

**Nature of operations:** The Syngenta AG group ("Syngenta") is a world leading agribusiness operating in the crop protection and seeds markets. Crop protection provides essential agricultural inputs, including chemical and biological products, enabling growers around the world to improve agricultural productivity and food quality. These include herbicides, insecticides, fungicides, seed treatments to control weeds, insects and diseases in crops, and professional solutions. In Seeds, the Syngenta AG group operates in the high value commercial sectors of field crops (including corn, oilseeds and cereals), vegetables and flowers.

**Basis of presentation and accounting policies:** The condensed consolidated interim financial statements ("interim financial statements") for the six months ended June 30, 2026 incorporate the financial statements of Syngenta AG and all of its subsidiaries. They have been prepared in accordance with IAS 34 *Interim Financial Reporting,* and should be read in conjunction with Syngenta's last annual consolidated financial statements as at and for the year ended December 31, 2025 ("last annual financial statements"). They do not include all of the information for a complete set of financial statements prepared in accordance with IFRS Accounting Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in Syngenta's financial position and performance since the last annual financial statements. Syngenta prepared its last annual financial statements in accordance with IFRS as issued by the International Accounting Standards Board (IASB).

The interim financial statements are presented in United States dollars ($) as this is the major currency in which revenues are denominated. Financial figures are presented in millions of dollars ($m) except where otherwise stated.

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated.

**Significant changes in the current reporting period:**

During the first six months of 2026, gross profit margin was two percentage points higher compared with the first six months of 2025 due to the effects of favourable product mix, lower cost of goods sold and favourable currency impacts. This improvement was more than offset by higher function costs, mainly driven by inflationary pressures and growth, and by increases in other operating expenses. The increase in other operating expenses was driven by losses from currency hedging of $26 million (2025: gains of $71 million), higher Global restructuring charges, as described in Note 6, and the impact of litigation settlements, as described in Note 7.

## Note 2: Seasonality of operations

The timing of Syngenta's sales, profit and cash flows throughout the year is influenced by seasonal factors. Operating in the agriculture sector, sales of Syngenta's products principally occur before and during the growing season. The northern hemisphere has a spring growing season and more sales occur and more profit is earned during the first half of the year than in the second half. Collections of trade receivables from customers in these northern hemisphere markets largely occur during the second half of the year. In the southern hemisphere more sales occur and more profit is earned during the first and last quarters of the year and because these southern hemisphere markets tend to have longer collection terms, collections also largely occur during the second half of the year. As a result of these seasonal factors, consolidated net income typically is higher, and operating cash flow typically is significantly lower, during the first half of the year than during the second half.

## Note 3: Accounting and reporting changes

Except as described below, the accounting policies applied in these interim condensed consolidated financial statements are the same as those applied in Syngenta's last annual financial statements.

Syngenta has adopted the following amendments from January 1, 2026:

- "Classification and Measurement of Financial Instruments", Amendments to IFRS 9 and IFRS 7;
- "Annual improvements to IFRS Accounting Standards – Volume 11"; and
- "Contracts Referencing Nature-dependent Electricity", Amendments to IFRS 9 and IFRS 7;

The adoption of these amendments had no material impact on these interim financial statements.

**Accounting Standards issued but not yet effective**

In April 2024, the International Accounting Standards Board issued IFRS 18 *Presentation and Disclosure in Financial Statements*, which replaces IAS 1 *Presentation of Financial Statements*. The standard is effective for annual reporting periods beginning on or after 1 January 2027, and Syngenta will first apply it in its interim and annual financial statements for the year ending 31 December 2027, with 2026 comparative information restated retrospectively.

**Key changes**

IFRS 18 introduces the following principal changes to the presentation and disclosure of financial statements:

- Structured consolidated income statement - Income and expenses are required to be classified into five categories: operating, investing, financing, income taxes, and discontinued operations. Two new mandatory subtotals must be presented on the face of the consolidated income statement: Operating profit or loss; and Profit or loss before financing and income taxes.
- Enhanced aggregation and disaggregation principles - The standard provides more prescriptive guidance on how to group and separate line items in the primary financial statements and in the notes.

- Management-defined performance measures (MPM) - Where subtotals of income and expenses are used in public communications to convey management's view of financial performance (for example, adjusted operating income or adjusted EBITDA), IFRS 18 requires details of those measures to be disclosed in a dedicated note to the financial statements and a reconciliation to the most directly comparable IFRS 18 subtotal.
- Amendments to IAS 7 - *Statement of Cash Flows* - IFRS 18 includes consequential amendments to IAS 7 that affect the presentation of the statement of cash flows in two respects: entities using the indirect method to report cash flows from operating activities will be required to use operating profit or loss (as defined by IFRS 18) as the starting point for the reconciliation to net cash from operating activities; and, the existing policy choices for classifying interest and dividend cash flows are removed. For entities whose main business activities do not include providing financing to customers or investing in financial assets (such as Syngenta), the amendments prescribe that interest paid and dividends paid are classified as financing activities; and interest received and dividends received are classified as investing activities. This will align the cash flow classification with the corresponding income and expense classification in the income statement under IFRS 18.

**Expected impact on Syngenta's financial statements**

Syngenta is currently performing a detailed impact assessment. Based on work completed to date, the principal effects are expected to be as follows:

- The consolidated income statement will be restructured to align with the requirement to present income and expenses into the five required categories with the two new mandatory subtotals. This will result in a change to the presentation of Syngenta's results but will not affect the recognition or measurement of any amounts.
- Income and expense items currently presented in Financial expense, net in the consolidated income statement such as net foreign exchange gains/(losses) and gains and losses on derivative instruments will be classified and presented in operating, investing, financing and income taxes categories based on the category of the item that gave rise to the gains or losses.
- Syngenta is evaluating which, if any, of its publicly communicated performance measures meet the definition of an MPM and will be subject to the new disclosure requirements.

Syngenta will continue to refine its assessment during the second half of 2026. The adoption of IFRS 18 will not affect Syngenta's total comprehensive income, net assets, or total net change in cash and cash equivalents. The changes are presentational and disclosure-related only.

## Note 4: Business combinations, divestments and other significant transactions

### Six months ended June 30, 2026

No material acquisitions, divestments or other significant transactions were completed in the six months ended June 30, 2026. Cash flow from Business divestments, net of cash divested related to deferred consideration for transactions completed in prior periods.

In May 2026, Syngenta entered into a binding agreement with Dümmen Orange to contribute the Syngenta Flowers business (“Flowers business”) to a joint venture entity in which Syngenta will hold a non-controlling equity interest. In consideration for the contribution, Syngenta will receive an equity interest in the joint venture and non-cash shareholder loans. Completion remains subject to regulatory clearances in multiple jurisdictions, employee consultation procedures and other customary closing conditions, and is expected in the last quarter of 2026.

The Flowers business has been classified as a disposal group held for sale in accordance with IFRS 5 “Non-current Assets Held for Sale and Discontinued Operations”. Upon reclassification, the disposal group was measured at its carrying amount of $128 million, which was lower than its estimated fair value less costs to sell. The Flowers business is reported within the Seeds segment.

The major classes of assets and liabilities of the disposal group as at June 30, 2026 are as follows:

| ($m) | Total |
|---|---|
| Inventories | 74 |
| Trade receivables and other current assets | 44 |
| Property, plant and equipment | 19 |
| Other non-current assets | 12 |
| **Assets held for sale** | **149** |
| | |
| Trade and other payables | 15 |
| Lease liabilities | 6 |
| **Liabilities held for sale** | **21** |

Due to materiality considerations, Assets held for sale and Liabilities held for sale are presented within “Other current assets” and “Other current liabilities” in the condensed consolidated balance sheet.

### Six months ended June 30, 2025

No material acquisitions, divestments or other significant transactions were completed in the six months ended June 30, 2025. Cash flow used for Business acquisitions, net of cash acquired and cash flow from Business divestments, net of cash divested related to deferred consideration for transactions completed in prior periods.

On July 1, 2024, Syngenta acquired 100 percent of the issued shares of Produtécnica Nordeste Comércio de Insumos Agrícolas Ltda. (“Produtecnica”), a limited liability company incorporated in Brazil, a distributor of agricultural products in the Brazilian states of Maranhao, Piaui and Tocantins of Brazil. The acquisition will enable Syngenta to strengthen its presence and explore further expansion opportunities in the North and Northeast regions of Brazil.

On December 24, 2024, Syngenta exercised a call option and obtained 100 percent control of Intrinsyx Bio Inc., (“Intrinsyx Bio”), a former associate in which Syngenta held a 40 percent equity ownership, for consideration of $50 million. Intrinsyx Bio is a US-based research and development company involved in the development of biological products for the Crop Protection segment and will enable Syngenta to develop new products for the biological market. Due to Syngenta’s previous 40 percent non-controlling ownership interest, the acquisition is considered to have occurred in stages, requiring Syngenta to fair value its existing Intrinsyx Bio investment immediately prior to the acquisition date.

The acquisition-date fair values of assets, liabilities and consideration for these acquisitions were not individually or in aggregate material and therefore were aggregated in the table below. The final purchase price allocations of the aforementioned acquisitions which were provisional as at December 31, 2024, were finalized during the six months ended June 30, 2025, as follows:

| **($m)** | **Total** |
|---|---|
| Cash and cash equivalents | 2 |
| Inventories | 15 |
| Trade receivables and other current assets | 33 |
| Property, plant and equipment | 1 |
| Intangible assets | 80 |
| Deferred tax and other non-current assets | 3 |
| Trade and other liabilities | (70) |
| Deferred tax liabilities | (22) |
| **Net assets acquired** | **42** |
| Purchase price, after agreed-upon adjustments | 53 |
| Fair value of 40 percent equity interest previously held by Syngenta | 33 |
| **Goodwill** | **44** |

The changes in fair values of the net assets acquired and goodwill recognized were not considered material to the 2024 consolidated financial statements and therefore the consolidated balance sheet as at December 31, 2024, was not restated.

## Note 5: Segmental information and analysis of revenue

Syngenta has five operating segments, consisting of the Crop Core, Professional Solutions, Field Crops, Vegetables and Flowers businesses. These have been aggregated into the global Crop Protection segment, consisting of Crop Core and Professional Solutions, and the global Seeds segment, consisting of Field Crops, Vegetables and Flowers. Aggregation is based on internal management structures and underlying economic similarity. Segment performance is managed based on segment operating income before costs from global restructuring plans, which is the measure of segment profit or loss presented and is based on the same accounting policies as consolidated operating income.

| **for the six months ended June 30, 2026 ($m)** | **Crop Protection** | **Seeds** | **Total segments** | **Global restructuring plans (Note 6)** | **Group** |
|---|---|---|---|---|---|
| Product sales | 6,027 | 1,830 | 7,857 | - | 7,857 |
| Royalty and license income | 1 | 167 | 168 | - | 168 |
| **Total segment sales** | **6,028** | **1,997** | **8,025** | **-** | **8,025** |
| Cost of goods sold | (3,591) | (997) | (4,588) | (28) | (4,616) |
| **Gross profit** | **2,437** | **1,000** | **3,437** | **(28)** | **3,409** |
| Marketing and distribution | (925) | (365) | (1,290) | - | (1,290) |
| Research and development | (388) | (214) | (602) | - | (602) |
| General and administrative | (287) | (114) | (401) | - | (401) |
| Other operating income | 146 | 1 | 147 | 2 | 149 |
| Other operating expense | (635) | (18) | (653) | (91) | (744) |
| **Operating income** | **348** | **290** | **638** | **(117)** | **521** |
| Financial expense, net | | | | | (170) |
| **Income before taxes** | | | | | **351** |

| **for the six months ended June 30, 2025 [1] ($m)** | **Crop Protection** | **Seeds** | **Total segments** | **Global restructuring plans (Note 6)** | **Group** |
|---|---|---|---|---|---|
| Product sales | 5,938 | 1,805 | 7,743 | - | 7,743 |
| Royalty and license income | 1 | 192 | 193 | - | 193 |
| **Total segment sales** | **5,939** | **1,997** | **7,936** | **-** | **7,936** |
| Cost of goods sold | (3,696) | (1,020) | (4,716) | - | (4,716) |
| **Gross profit** | **2,243** | **977** | **3,220** | **-** | **3,220** |
| Marketing and distribution | (835) | (359) | (1,194) | - | (1,194) |
| Research and development | (324) | (183) | (507) | - | (507) |
| General and administrative | (237) | (105) | (342) | (4) | (346) |
| Other operating income | 112 | 56 | 168 | 8 | 176 |
| Other operating expense | (122) | (15) | (137) | (25) | (162) |
| **Operating income** | **837** | **371** | **1,208** | **(21)** | **1,187** |
| Financial expense, net | | | | | (256) |
| **Income before taxes** | | | | | **931** |

1 2025 has been reclassified to reflect the Other operating income and Other operating expense categories which were previously grouped within General and administrative

All activities were in respect of continuing operations.

The analysis of revenue by major product line is as follows:

| **for the six months ended June 30,**<br>**($m)** | **2026** | **2025** |
|---|---|---|
| Selective herbicides | 1,542 | 1,574 |
| Non-selective herbicides | 364 | 310 |
| Fungicides | 1,754 | 1,770 |
| Insecticides | 1,033 | 969 |
| Seedcare | 573 | 536 |
| Professional solutions | 315 | 308 |
| Biologicals | 259 | 232 |
| Other crop protection | 238 | 279 |
| **Total Crop Protection** | **6,078** | **5,978** |
| Corn and soybean | 1,108 | 1,136 |
| Diverse field crops | 359 | 335 |
| Vegetables | 423 | 418 |
| Flowers | 120 | 114 |
| **Total Seeds** | **2,010** | **2,003** |
| Elimination of Crop Protection sales to Seeds | (50) | (39) |
| Elimination of Seeds sales to Crop Protection | (13) | (6) |
| **Total sales** | **8,025** | **7,936** |

The analysis of revenue by primary geographical market is as follows:

| **for the six months ended June 30,**<br>**($m)** | **2026** | **2025[1]** |
|---|---|---|
| Asia, Middle East and Africa | 1,665 | 1,641 |
| Europe | 2,181 | 2,029 |
| Latin America | 1,815 | 1,788 |
| North America | 1,991 | 2,118 |
| Other | 373 | 360 |
| **Total sales** | **8,025** | **7,936** |

1 To be consistent with 2026, the 2025 comparative figures have been reclassified to present intra-group sales made to China as part of Asia, Middle East and Africa instead of Other

## Note 6: Global restructuring plans

Global restructuring plans represent the effect on reported performance of initiating and enabling business changes that are considered major and that, in the opinion of management, will have a material effect on the nature and focus of Syngenta's operations, and therefore require separate disclosure from the segment information to provide a more thorough understanding of business performance. This includes the incremental costs of closing, restructuring or relocating existing operations, and gains or losses from related asset disposals.

Global restructuring plans also include the effects of analyzing and preparing for potential industry consolidation transactions, as well as completing and integrating significant business combinations and divestments, including related transaction costs, gains and losses. Recurring costs of normal business operations and routine asset disposal gains and losses, including those arising from sale and leaseback transactions carried out to optimize Syngenta AG group financing, are excluded.

Impairment losses associated with major restructuring as well as impairment losses and reversals of impairment losses resulting from major changes in the markets in which a reported segment operates are also included in Global restructuring plans.

Global restructuring plans consist of the following:

| **for the six months ended June 30,**<br>**($m)** | **2026** | **2025** |
|---|---|---|
| Productivity programs and other restructuring costs | (85) | (14) |
| Impairment and accelerated depreciation | (28) | (4) |
| Divestment gains | 2 | 8 |
| Acquisition and integration costs | (6) | (11) |
| **Total** | **(117)** | **(21)** |

Global restructuring plans are presented within the consolidated income statement as follows:

| **for the six months ended June 30,**<br>**($m)** | **2026** | **2025** |
|---|---|---|
| Reported as: | | |
| Cost of goods sold | (28) | - |
| General and administrative | - | (4) |
| Other operating income | 2 | 8 |
| Other operating expense | (91) | (25) |
| **Total** | **(117)** | **(21)** |

### Productivity programs and other restructuring costs

### 2026

Cash costs of $85 million were incurred for productivity initiatives, including $59 million of severance and other employee-related costs and $9 million of environmental remediation and dismantling associated with the closure of Crop Protection facilities in Europe, $10 million for system projects covering Procurement, Production and Supply and migrations as part of a multi-year initiative targeting a global ERP platform, and $7 million across a number of individually small initiatives.

**2025**
Cash costs of $14 million were incurred for productivity initiatives, including $8 million for system projects covering Procurement, Production and Supply and migrations as part of a multi-year initiative targeting a global ERP platform, and $6 million across a number of individually small initiatives.

**Impairment and accelerated depreciation**

**2026**
Impairment and other non-cash items include $24 million of accelerated depreciation of manufacturing facilities resulting from the adoption of shorter asset lives due to the above-mentioned closure of facilities in Europe, $3 million of inventory write-downs following restructuring initiatives and $1 million of other small impairments where asset values were not supported by future business plans.

**2025**
Impairment and other non-cash items were immaterial in the first six months of 2025.

**Divestment gains**

**2026**
Divestment gains include $2 million relating to the divestment of sites within the Seeds business due to strategic decisions to exit certain geographies and crops.

**2025**
Divestment gains included $2 million relating to the divestment of sites within the Seeds business as mentioned above, and a $6 million bargain purchase gain resulting from a small acquisition.

**Acquisition and integration costs**

**2026**
Cash costs include $3 million incurred for merger and acquisition projects and transaction costs, and $3 million incurred for projects to integrate completed acquisitions.

**2025**
Cash costs included $8 million incurred for merger and acquisition projects and transaction costs, and $3 million incurred for projects to integrate completed acquisitions.

## Note 7: Litigation matters

During the first six months of 2026, Syngenta paid approximately $300 million, included within Cash paid in respect of other provisions in the Consolidated Cash Flow Statement, in respect of legal and product liabilities for which provisions were previously recognized.

During June 2026, Syngenta reached a confidential agreement to settle a number of pending product liability claims. Syngenta believes that all of these claims are without merit and the settlement is not an admission of liability but solely for the purpose of bringing to an end these claims.

Detailed information regarding the amount, timing and uncertainties of potential outflows from litigation matters are not disclosed, in accordance with IFRS Accounting Standards, because such disclosure could seriously prejudice the Group’s position in these matters.

## Note 8: Non-cash and other reconciling items included in income before taxes

| for the six months ended June 30,<br>($m) | 2026 | 2025 |
|---|---|---|
| Depreciation, amortization and impairment of: | | |
| Property, plant and equipment | 248 | 214 |
| Right-of-use assets | 77 | 70 |
| Intangible assets | 214 | 184 |
| Less: depreciation and amortization capitalized | (26) | (25) |
| Deferred revenue and other gains and losses | 26 | 45 |
| Gains on disposal of non-current assets | (17) | - |
| Charges in respect of pension provisions | 36 | 32 |
| Charges in respect of other provisions | 70 | 39 |
| Financial expense, net | 170 | 256 |
| Losses/(gains) on hedges reported in operating income | 17 | (69) |
| **Total** | **815** | **746** |

## Note 9: Principal currency translation rates

As an international business selling in over 100 countries and having major manufacturing and research and development facilities in Switzerland, the UK, the USA, France and Brazil, movements in currencies impact Syngenta's business performance. The principal currencies and exchange rates against the US dollar used in preparing the interim condensed consolidated financial statements were as follows:

| | | Average six months ended June 30, | | June 30, | June 30, | December 31, |
|---|---|---|---|---|---|---|
| **Per $** | | **2026** | **2025** | **2026** | **2025** | **2025** |
| Brazilian real | BRL | 5.15 | 5.75 | 5.18 | 5.46 | 5.50 |
| Swiss franc | CHF | 0.78 | 0.87 | 0.81 | 0.80 | 0.79 |
| Euro | EUR | 0.85 | 0.93 | 0.88 | 0.85 | 0.85 |
| British pound sterling | GBP | 0.74 | 0.78 | 0.75 | 0.73 | 0.74 |
| Russian ruble | RUB | 76.99 | 90.55 | 78.61 | 78.60 | 81.34 |
| Chinese yuan | CNY | 6.88 | 7.28 | 6.79 | 7.16 | 6.98 |

The average rates presented above are an average of the monthly rates used to prepare the interim condensed consolidated income and cash flow statements. The period end rates were used for the preparation of the condensed consolidated balance sheet.

## Note 10: Issuances, repurchases and repayments of debt and equity securities

**2026**

In April 2026, Syngenta repaid a EUR 900 million bond at maturity.

**2025**

In April 2025, Syngenta repaid a $677 million bond at maturity.

In June 2025, the $3 billion multi-bank syndicated revolving credit facility for an original term of 5 years, with option for two one-year extensions was confirmed to be extended by a year, maturing in July 2030.

## Note 11: Financial instruments

The following table shows the carrying amounts and fair values of financial assets and liabilities by category of financial instrument and a reconciliation to where they are presented on the balance sheet at June 30, 2026 and December 31, 2025. The fair value hierarchy is shown for those financial assets and liabilities that are carried at fair value in the condensed consolidated balance sheet.

| | Carrying amount (based on measurement basis) | | | | | |
|---|---|---|---|---|---|---|
| **at June 30, 2026 ($m)** | Amortized cost | Fair value level 1 | Fair value level 2 | Fair value level 3 | Total | Comparison fair value |
| Cash and cash equivalents | 977 | - | - | - | 977 | 977 |
| Trade receivables: | | | | | | |
| At amortized cost | 5,611 | - | - | - | 5,611 | 5,611 |
| At fair value through OCI | - | - | 1,727 | - | 1,727 | 1,727 |
| **Total** | | | | | **7,338** | |
| Other accounts receivable: | | | | | | |
| Financial assets | 915 | - | - | - | 915 | 915 |
| Non-financial assets | - | - | - | - | 509 | - |
| **Total** | | | | | **1,424** | |
| Derivative and other financial assets: | | | | | | |
| Derivative financial assets | - | 5 | 479 | - | 484 | 484 |
| Marketable securities | 60 | - | - | - | 60 | 61 |
| Other current financial assets | 14 | - | - | - | 14 | 14 |
| **Total** | | | | | **558** | |
| Financial and other non-current assets: | | | | | | |
| Equity investments at fair value through OCI | - | - | - | 103 | 103 | 103 |
| Derivative financial assets | - | - | 131 | - | 131 | 131 |
| Loans and other non-current receivables | 69 | - | - | - | 69 | 69 |
| Non-current marketable securities | 180 | - | - | - | 180 | 179 |
| Non-financial assets | - | - | - | - | 1,128 | - |
| **Total** | | | | | **1,611** | |

| at June 30, 2026 ($m) | Carrying amount (based on measurement basis) Amortized cost | Fair value level 1 | Fair value level 2 | Fair value level 3 | Total | Comparison fair value |
|---|---|---|---|---|---|---|
| Trade accounts payable | 6,720 | - | - | - | 6,720 | 6,720 |
| Current financial debt and other financial liabilities: | | | | | | |
| Derivative financial liabilities | - | - | 144 | - | 144 | 144 |
| Lease liabilities | 153 | - | - | - | 153 | - |
| Other non-derivative financial liabilities | 6,780 | - | - | - | 6,780 | 6,780 |
| **Total** | | | | | **7,077** | |
| Other current liabilities: | | | | | | |
| Financial liabilities | 158 | - | - | - | 158 | 158 |
| Non-financial liabilities | - | - | - | - | 1,440 | - |
| **Total** | | | | | **1,598** | |
| Financial debt and other non-current liabilities: | | | | | | |
| Lease liabilities | 1,294 | - | - | - | 1,294 | - |
| Other non-derivative financial liabilities | 5,151 | - | - | - | 5,151 | 5,120 |
| Non-financial liabilities | - | - | - | - | 206 | - |
| **Total** | | | | | **6,651** | |

| at December 31, 2025 ($m) | Carrying amount (based on measurement basis) Amortized cost | Fair value level 1 | Fair value level 2 | Fair value level 3 | Total | Comparison fair value |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 677 | - | - | - | 677 | 677 |
| Trade receivables: | | | | | | |
| At amortized cost | 4,267 | - | - | - | 4,267 | 4,267 |
| At fair value through OCI | - | - | 1,338 | - | 1,338 | 1,338 |
| **Total** | | | | | **5,605** | |
| Other accounts receivable: | | | | | | |
| Financial assets | 676 | - | - | - | 676 | 676 |
| Non-financial assets | - | - | - | - | 574 | - |
| **Total** | | | | | **1,250** | |
| Derivative and other financial assets: | | | | | | |
| Derivative financial assets | - | 3 | 140 | - | 143 | 143 |
| Marketable securities | 89 | - | - | - | 89 | 91 |
| Other current financial assets | 221 | - | - | - | 221 | 221 |
| **Total** | | | | | **453** | |
| Financial and other non-current assets: | | | | | | |
| Equity investments at fair value through OCI | - | - | - | 124 | 124 | 124 |
| Derivative financial assets | - | - | 82 | - | 82 | 82 |
| Loans and other non-current receivables | 153 | - | - | - | 153 | 153 |
| Non-current marketable securities | 238 | - | - | - | 238 | 231 |
| Non-financial assets | - | - | - | - | 934 | - |
| **Total** | | | | | **1,531** | |

| at December 31, 2025<br>($m) | Carrying amount (based on measurement basis)<br>Amortized cost | Fair value level 1 | Fair value level 2 | Fair value level 3 | Total | Comparison fair value |
|---|---|---|---|---|---|---|
| Trade accounts payable | 5,926 | - | - | - | 5,926 | 5,926 |
| Current financial debt and other financial liabilities: | | | | | | |
| Derivative financial liabilities | - | - | 286 | - | 286 | 286 |
| Lease liabilities | 151 | - | - | - | 151 | - |
| Other non-derivative financial liabilities | 3,565 | - | - | - | 3,565 | 3,565 |
| **Total** | | | | | **4,002** | |
| Other current liabilities: | | | | | | |
| Financial liabilities | 157 | - | - | - | 157 | 157 |
| Non-financial liabilities | - | - | - | - | 1,357 | - |
| **Total** | | | | | **1,514** | |
| Financial debt and other non-current liabilities: | | | | | | |
| Derivative financial liabilities | - | - | 14 | - | 14 | 14 |
| Lease liabilities | 1,298 | - | - | - | 1,298 | - |
| Other non-derivative financial liabilities | 5,658 | - | - | - | 5,658 | 5,542 |
| Non-financial liabilities | - | - | - | - | 189 | - |
| **Total** | | | | | **7,159** | |

The levels of fair value hierarchy used above are defined as follows:

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data.

The valuation techniques and inputs used by Syngenta to derive level 2 and level 3 fair value measurements of the above financial assets and liabilities are as described in Note 25 to Syngenta's last annual financial statements. During the six months ended June 30, 2026 there were no material movements in equity investments measured at fair value through OCI; no transfers between the fair value and amortized cost categories; and no material transfers between level 1 and level 2 of the fair value hierarchy or into or out of level 3 of the fair value hierarchy.

## Note 12: Related party transactions

During the six months ended June 30, 2026, goods and services provided to fellow subsidiaries of Syngenta Group were $285 million (six months ended June 30, 2025: $193 million), and goods and services provided by fellow subsidiaries of Syngenta Group were $351 million (six months ended June 30, 2025: $368 million).

At June 30, 2026, the Syngenta AG group had accounts receivable from fellow subsidiaries of Syngenta Group of $567 million (December 31, 2025: $490 million) and accounts payable and other current liabilities to fellow subsidiaries of Syngenta Group of $633 million (December 31, 2025: $233 million). This amount includes $350 million of dividend payable to Syngenta Group (HK) Holdings Co. Ltd, recognized in Other current liabilities in the Consolidated Balance Sheet (December 31, 2025: nil).

The following borrowings were raised from or repaid to fellow subsidiaries of Syngenta Group during the six months ended June 30, 2026:

- In March 2026, a $500 million loan was raised from a fellow subsidiary of Syngenta Group, increasing an existing $700 million loan maturing in 2030 to $850 million and an existing $500 million loan maturing in 2028 to $850 million.
- In March 2026, a CNY 3.5 billion loan from a fellow subsidiary of Syngenta Group was repaid at maturity.
- In April 2026, a $500 million loan from a fellow subsidiary of Syngenta Group was repaid at maturity.

In total, as at June 30, 2026, borrowings from fellow subsidiaries of Syngenta Group were $6.4 billion, including CNY 12.8 billion at June 30, 2026 exchange rates (December 31, 2025: total borrowings of $4.1 billion, including CNY 16.3 billion at December 31, 2025 exchange rates).

## Note 13: Subsequent events

On July 10, 2026, Fitch Ratings upgraded Syngenta AG's credit rating from BBB/F3 to A-/F2, with a Stable Outlook. The upgrade followed Fitch's reassessment of the linkages between Syngenta AG and Syngenta Group Co. Ltd, the parent company of Syngenta Group, including its assessment of the strategic importance of Syngenta AG's research and development capabilities and patent portfolio within the Syngenta Group.

No other events occurred between the balance sheet date and the date on which these interim financial statements were approved by the Board of Directors that would require adjustment to or disclosure in the interim financial statements.

The interim financial statements were authorized for issue by the Board of Directors on August 26, 2026.

## Financial summary

| for the six months ended June 30, ($m) | Before global restructuring plans [1] 2026 | Before global restructuring plans [1] 2025 | Global restructuring plans 2026 | Global restructuring plans 2025 | As reported under IFRS 2026 | As reported under IFRS 2025 |
|---|---|---|---|---|---|---|
| **Sales** | **8,025** | **7,936** | **-** | **-** | **8,025** | **7,936** |
| **Gross profit** | **3,437** | **3,220** | **(28)** | **-** | **3,409** | **3,220** |
| Marketing and distribution | (1,290) | (1,194) | - | - | (1,290) | (1,194) |
| Research and development | (602) | (507) | - | - | (602) | (507) |
| General and administrative | (401) | (342) | - | (4) | (401) | (346) |
| Other operating income | 147 | 168 | 2 | 8 | 149 | 176 |
| Other operating expense | (653) | (137) | (91) | (25) | (744) | (162) |
| **Operating income** | **638** | **1,208** | **(117)** | **(21)** | **521** | **1,187** |
| **Income before taxes** | **468** | **952** | **(117)** | **(21)** | **351** | **931** |
| Income tax expense | (194) | (354) | 21 | 4 | (173) | (350) |
| **Net income** | **274** | **598** | **(96)** | **(17)** | **178** | **581** |
| Attributable to non-controlling interests | 1 | 2 | - | - | 1 | 2 |
| **Attributable to Syngenta AG shareholder** | **273** | **596** | **(96)** | **(17)** | **177** | **579** |

| | 2026 | 2025 | 2026 CER [2] |
|---|---|---|---|
| **EBITDA [3]** | **1,126** | **1,650** | |
| **EBITDA margin** | **14.0%** | **20.8%** | **15.6%** |
| **Tax rate on results excluding global restructuring plans** | **41%** | **37%** | |
| **Free cash flow [4]** | **(2,138)** | **(1,597)** | |
| **Debt/equity gearing [5]** | **155%** | **148%** | |
| **Net debt [5]** | **11,299** | **11,954** | |

1 *For further analysis of global restructuring plans, see Note 6 on page 13. Net income excluding global restructuring plans is provided as additional information and not as an alternative to net income determined in accordance with IFRS.*

2 *For a description of CER see Appendix A on page 21.*

3 *EBITDA is defined in Appendix B on page 21.*

4 *For a description of free cash flow, see Appendix C on page 22.*

5 *For a description of net debt and the calculation of debt/equity gearing, see Appendix D on page 23.*

## Appendix A: Constant exchange rates (CER)

Results in this report from one period to another period are, where appropriate, compared using constant exchange rates (CER). To present that information, current period results for entities reporting in currencies other than US dollars are converted into US dollars at the prior period's exchange rates, rather than at the exchange rates for the current year. CER margin percentage for EBITDA is calculated by the ratio of this measure to sales after restating the measure and sales at prior period exchange rates. The CER presentation indicates the underlying business performance before taking into account currency exchange fluctuations.

## Appendix B: Reconciliation of EBITDA to net income

EBITDA is defined as earnings before interest, tax, non-controlling interests, depreciation, amortization, impairment and global restructuring plans. Information concerning EBITDA has been included as it is used by management and by investors as a supplementary measure of operating performance. Management excludes global restructuring plans from EBITDA in order to focus on results excluding items affecting comparability from one period to the next. EBITDA is not a measure of cash liquidity or financial performance under generally accepted accounting principles and the EBITDA measures used by Syngenta may not be comparable to other similarly titled measures of other companies. EBITDA should not be construed as an alternative to operating income or cash flow as determined in accordance with generally accepted accounting principles.

| **for the six months ended June 30,<br>($m)** | **2026** | **2025** |
|---|---|---|
| **Net income attributable to Syngenta AG shareholder** | **177** | **579** |
| Non-controlling interests | 1 | 2 |
| Income tax expense | 173 | 350 |
| Financial expense, net | 170 | 256 |
| Global restructuring plans | 117 | 21 |
| Depreciation, amortization and impairment | 488 | 442 |
| **EBITDA** | **1,126** | **1,650** |

## Appendix C: Free cash flow

Free cash flow comprises cash flow from operating and investing activities:

- excluding investments in and proceeds from marketable securities, which are included in investing activities;
- excluding cash flows from and used for foreign exchange movements and settlement of related hedges on inter-company loans, which are included in operating activities; and
- including cash flows from acquisitions of non-controlling interests, which are included in financing activities.

Free cash flow is not a measure of financial performance under generally accepted accounting principles and the free cash flow measure used by Syngenta may not be identical to similarly titled measures in other companies. Free cash flow has been included as many investors consider it to be a useful supplementary measure of cash generation.

| **for the six months ended June 30,**<br>**($m)** | **2026** | **2025** |
|---|---|---|
| Cash flow used for operating activities | (1,696) | (1,193) |
| Cash flow used for investing activities | (352) | (342) |
| Excluding: cash flow (from)/used for marketable securities | (97) | 36 |
| Excluding: cash flow used for/(from) foreign exchange movements and settlement of hedges of inter-company loans | 7 | (98) |
| **Free cash flow** | **(2,138)** | **(1,597)** |

## Appendix D: Net debt reconciliation

Net debt comprises total debt net of cash and cash equivalents and marketable securities. Net debt is not a measure of financial position under generally accepted accounting principles and the net debt measure used by Syngenta may not be comparable to the similarly titled measure of other companies. Net debt has been included as many investors consider it to be a useful measure of financial position and risk. The following table provides a reconciliation of movements in net debt during the period:

**for the six months ended June 30,**

| ($m) | 2026 | 2025 |
|---|---|---|
| **Opening balance at January 1** | **9,527** | **9,399** |
| Other and non-cash items | 86 | 53 |
| Cash paid on financing-related derivatives | 155 | - |
| Cash (received)/paid under Credit Support Annex agreements, net | (589) | 678 |
| Foreign exchange effect on net debt | (18) | 248 |
| Proceeds from partial divestment of interest in subsidiary | - | (21) |
| Free cash flow | 2,138 | 1,597 |
| **Closing balance at June 30** | **11,299** | **11,954** |
| **Components of closing balance:** | | |
| Cash and cash equivalents | (977) | (971) |
| Marketable securities [1] | (240) | (421) |
| Current financial debt [2] | 6,074 | 6,941 |
| Non-current financial debt [3] | 6,442 | 6,405 |
| **Closing balance at June 30** | **11,299** | **11,954** |

1 *Long-term marketable securities are included in Financial and other non-current assets. Short-term marketable securities are included in Derivative and other financial assets.*

2 *Included in Current financial debt and other financial liabilities.*

3 *Included in Financial debt and other non-current liabilities.*

The following table presents the derivation of the debt/equity gearing ratio at June 30, 2026 and 2025:

| ($m) | 2026 | 2025 |
|---|---|---|
| Net debt | 11,299 | 11,954 |
| Shareholder's equity | 7,303 | 8,076 |
| **Debt/Equity gearing ratio (%)** | **155** | **148** |